FDA Determines Regulatory Review Period for KOVALTRY Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for KOVALTRY, a human biological product, as required by law, following a submission to the U.S. Patent and Trademark Office (USPTO).